Delivery of bortezomib with nanoparticles for basal-like triple-negative breast cancer therapy

Journal of Controlled Release

Volumn 208, Issue , 2015, Pages 14-24

  Shen, Song ^a   Du, Xiao Jiao ^a   Liu, Jing ^a   Sun, Rong ^b   Zhu, Yan Hua ^a   Wang, Jun ^a,b  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

Basal like triple negative breast cancer; Bortezomib; Cancer stem cells; Nanoparticle; Poly(ethylene glycol) block poly(d,l lactide)

Indexed keywords

CELL DEATH; DIAGNOSIS; DRUG DELIVERY; DRUG THERAPY; NANOPARTICLES; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; POLYOLS; STEM CELLS; TUMORS;

AMPHIPHILIC CO-POLYMERS; BORTEZOMIB; CANCER STEM CELLS; CIRCULATION HALF-LIFES; ENCAPSULATED NANOPARTICLES; POLY (D ,L-LACTIDE); PROLIFERATION INHIBITION; TRIPLE-NEGATIVE BREAST CANCERS;

DISEASES;

ANTINEOPLASTIC AGENT; BORTEZOMIB; EXCIPIENT; LACTIC ACID DERIVATIVE; MACROGOL DERIVATIVE; NANOPARTICLE; POLY(LACTIC ACID-ETHYLENE GLYCOL); PROTEASOME;

ANIMAL; APOPTOSIS; CANCER STEM CELL; CELL PROLIFERATION; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG FORMULATION; FEMALE; HALF LIFE TIME; HUMAN; MOUSE; NONOBESE DIABETIC MOUSE; SCID MOUSE; TRIPLE NEGATIVE BREAST NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORTEZOMIB; CELL PROLIFERATION; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; EXCIPIENTS; FEMALE; HALF-LIFE; HUMANS; LACTATES; MICE; MICE, INBRED NOD; MICE, SCID; NANOPARTICLES; NEOPLASTIC STEM CELLS; POLYETHYLENE GLYCOLS; PROTEASOME ENDOPEPTIDASE COMPLEX; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84939990355     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.12.043     Document Type: Article

References (50)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J. Clin. 64 2014 9 29
2. L. Hutchinson Breast cancer: challenges, controversies, breakthroughs Nat. Rev. Clin. Oncol. 7 2010 669 670
3. S. Santagata, A. Thakkar, A. Ergonul, B. Wang, T. Woo, R. Hu, J.C. Harrell, G. McNamara, M. Schwede, A.C. Culhane, D. Kindelberger, S. Rodig, A. Richardson, S.J. Schnitt, R.M. Tamimi, and T.A. Ince Taxonomy of breast cancer based on normal cell phenotype predicts outcome J. Clin. Invest. 124 2014 859 870
4. W.D. Foulkes, I.E. Smith, and J.S. Reis-Filho Triple-negative breast cancer N. Engl. J. Med. 363 2010 1938 1948
5. A. Bosch, P. Eroles, R. Zaragoza, J.R. Vina, and A. Lluch Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research Cancer Treat. Rev. 36 2010 206 215
6. D.B. Allison, X. Cui, G.P. Page, and M. Sabripour Microarray data analysis: from disarray to consolidation and consensus Nat. Rev. Genet. 7 2006 55 65
7. A. Prat, B. Adamo, M.C. Cheang, C.K. Anders, L.A. Carey, and C.M. Perou Molecular characterization of basal-like and non-basal-like triple-negative breast cancer Oncologist 18 2013 123 133
8. M.J. van de Vijver, Y.D. He, L.J. van't Veer, H. Dai, A.A. Hart, D.W. Voskuil, G.J. Schreiber, J.L. Peterse, C. Roberts, M.J. Marton, M. Parrish, D. Atsma, A. Witteveen, A. Glas, L. Delahaye, T. van der Velde, H. Bartelink, S. Rodenhuis, E.T. Rutgers, S.H. Friend, and R. Bernards A gene-expression signature as a predictor of survival in breast cancer N. Engl. J. Med. 347 2002 1999 2009
9. P. Gazinska, A. Grigoriadis, J.P. Brown, R.R. Millis, A. Mera, C.E. Gillett, L.H. Holmberg, A.N. Tutt, and S.E. Pinder Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles Mod. Pathol. 26 2013 955 966
10. E.A. Rakha, J.S. Reis-Filho, and I.O. Ellis Basal-like breast cancer: a critical review J. Clin. Oncol. 26 2008 2568 2581
11. M. Clarke, R. Collins, C. Davies, J. Godwin, R. Gray, and R. Peto Early breast cancer trialists collaborative, Tamoxifen for early breast cancer: an overview of the randomised trials Lancet 351 1998 1451 1467
12. J. Crown, J. O'Shaughnessy, and G. Gullo Emerging targeted therapies in triple-negative breast cancer Ann. Oncol. 23 Suppl. 6 2012 vi56 vi65
13. C. Liedtke, C. Mazouni, K.R. Hess, F. Andre, A. Tordai, J.A. Mejia, W.F. Symmans, A.M. Gonzalez-Angulo, B. Hennessy, M. Green, M. Cristofanilli, G.N. Hortobagyi, and L. Pusztai Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J. Clin. Oncol. 26 2008 1275 1281
14. T. Reya, S.J. Morrison, M.F. Clarke, and I.L. Weissman Stem cells, cancer, and cancer stem cells Nature 414 2001 105 111
15. M. Dean, T. Fojo, and S. Bates Tumour stem cells and drug resistance Nat. Rev. Cancer 5 2005 275 284
16. E. Lonardo, P.C. Hermann, M.T. Mueller, S. Huber, A. Balic, I. Miranda-Lorenzo, S. Zagorac, S. Alcala, I. Rodriguez-Arabaolaza, J.C. Ramirez, R. Torres-Ruiz, E. Garcia, M. Hidalgo, D.A. Cebrian, R. Heuchel, M. Lohr, F. Berger, P. Bartenstein, A. Aicher, and C. Heeschen Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy Cell Stem Cell 9 2011 433 446
17. G. Driessens, B. Beck, A. Caauwe, B.D. Simons, and C. Blanpain Defining the mode of tumour growth by clonal analysis Nature 488 2012 527 530
18. J.Y. Lang, J.L. Hsu, F. Meric-Bernstam, C.J. Chang, Q. Wang, Y. Bao, H. Yamaguchi, X. Xie, W.A. Woodward, D. Yu, G.N. Hortobagyi, and M.C. Hung BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment Cancer Cell 20 2011 341 356
19. N.E. Bhola, J.M. Balko, T.C. Dugger, M.G. Kuba, V. Sanchez, M. Sanders, J. Stanford, R.S. Cook, and C.L. Arteaga TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer J. Clin. Invest. 123 2013 1348 1358
20. B. Beck, and C. Blanpain Unravelling cancer stem cell potential Nat. Rev. Cancer 13 2013 727 738
21. J. Domingo-Domenech, S.J. Vidal, V. Rodriguez-Bravo, M. Castillo-Martin, S.A. Quinn, R. Rodriguez-Barrueco, D.M. Bonal, E. Charytonowicz, N. Gladoun, J. de la Iglesia-Vicente, D.P. Petrylak, M.C. Benson, J.M. Silva, and C. Cordon-Cardo Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells Cancer Cell 22 2012 373 388
22. P.B. Gupta, T.T. Onder, G. Jiang, K. Tao, C. Kuperwasser, R.A. Weinberg, and E.S. Lander Identification of selective inhibitors of cancer stem cells by high-throughput screening Cell 138 2009 645 659
23. E. Sachlos, R.M. Risueno, S. Laronde, Z. Shapovalova, J.H. Lee, J. Russell, M. Malig, J.D. McNicol, A. Fiebig-Comyn, M. Graham, M. Levadoux-Martin, J.B. Lee, A.O. Giacomelli, J.A. Hassell, D. Fischer-Russell, M.R. Trus, R. Foley, B. Leber, A. Xenocostas, E.D. Brown, T.J. Collins, and M. Bhatia Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells Cell 149 2012 1284 1297
24. F. Petrocca, G. Altschuler, S.M. Tan, M.L. Mendillo, H. Yan, D.J. Jerry, A.L. Kung, W. Hide, T.A. Ince, and J. Lieberman A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells Cancer Cell 24 2013 182 196
25. J. Adams The proteasome: a suitable antineoplastic target Nat. Rev. Cancer 4 2004 349 360
26. P.G. Richardson, B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, D. Irwin, S.V. Rajkumar, G. Srkalovic, M. Alsina, R. Alexanian, D. Siegel, R.Z. Orlowski, D. Kuter, S.A. Limentani, S. Lee, T. Hideshima, D.L. Esseltine, M. Kauffman, J. Adams, D.P. Schenkein, and K.C. Anderson A phase 2 study of bortezomib in relapsed, refractory myeloma N. Engl. J. Med. 348 2003 2609 2617
27. J. Laubach, and P. Richardson Hematology: bortezomib and dexamethasone induction for multiple myeloma Nat. Rev. Clin. Oncol. 8 2011 8 10
28. G.V. Scagliotti, P. Germonpre, L. Bosquee, J. Vansteenkiste, R. Gervais, D. Planchard, M. Reck, F. De Marinis, J.S. Lee, K. Park, B. Biesma, S. Gans, R. Ramlau, A. Szczesna, A. Makhson, G. Manikhas, B. Morgan, Y. Zhu, K.C. Chan, and J. von Pawel A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer Lung Cancer 68 2010 420 426
29. A. Goy, A. Younes, P. McLaughlin, B. Pro, J.E. Romaguera, F. Hagemeister, L. Fayad, N.H. Dang, F. Samaniego, M. Wang, K. Broglio, B. Samuels, F. Gilles, A.H. Sarris, S. Hart, E. Trehu, D. Schenkein, F. Cabanillas, and A.M. Rodriguez Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma J. Clin. Oncol. 23 2005 667 675
30. C.N. Papandreou, and C.J. Logothetis Bortezomib as a potential treatment for prostate cancer Cancer Res. 64 2004 5036 5043
31. C.H. Yang, A.M. Gonzalez-Angulo, J.M. Reuben, D.J. Booser, L. Pusztai, S. Krishnamurthy, D. Esseltine, J. Stec, K.R. Broglio, R. Islam, G.N. Hortobagyi, and M. Cristofanilli Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits Ann. Oncol. 17 2006 813 817
32. R.H. Engel, J.A. Brown, J.H. Von Roenn, R.M. O'Regan, R. Bergan, S. Badve, A. Rademaker, and W.J. Gradishar A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience Cancer Invest. 25 2007 733 737
33. J.P. Vanderloo, M.L. Pomplun, L.C. Vermeulen, and J.M. Kolesar Stability of unused reconstituted bortezomib in original manufacturer vials J. Clin. Oncol. 17 2011 400 402
34. W. Wei, Z.G. Yue, J.B. Qu, H. Yue, Z.G. Su, and G.H. Ma Galactosylated nanocrystallites of insoluble anticancer drug for liver-targeting therapy: an in vitro evaluation Nanomedicine (Lond.) 5 2010 589 596
35. Z.G. Chen Small-molecule delivery by nanoparticles for anticancer therapy Trends Mol. Med. 16 2010 594 602
36. A.Z. Wang, R. Langer, and O.C. Farokhzad Nanoparticle delivery of cancer drugs Annu. Rev. Med. 63 2012 185 198
37. M.E. Davis, Z.G. Chen, and D.M. Shin Nanoparticle therapeutics: an emerging treatment modality for cancer Nat. Rev. Drug Discov. 7 2008 771 782
38. R.J. Li, X. Ying, Y. Zhang, R.J. Ju, X.X. Wang, H.J. Yao, Y. Men, W. Tian, Y. Yu, L. Zhang, R.J. Huang, and W.L. Lu All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells J. Control. Release 149 2011 281 291
39. Y. Liu, W.L. Lu, J. Guo, J. Du, T. Li, J.W. Wu, G.L. Wang, J.C. Wang, X. Zhang, and Q. Zhang A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes J. Control. Release 129 2008 18 25
40. R.Z. Xiao, Z.W. Zeng, G.L. Zhou, J.J. Wang, F.Z. Li, and A.M. Wang Recent advances in PEG-PLA block copolymer nanoparticles Int. J. Nanomedicine 5 2010 1057 1065
41. N. Saito, T. Okada, H. Horiuchi, N. Murakami, J. Takahashi, M. Nawata, H. Ota, K. Nozaki, and K. Takaoka A biodegradable polymer as a cytokine delivery system for inducing bone formation Nat. Biotechnol. 19 2001 332 335
42. M.G. Nava-Arzaluz, E. Pinon-Segundo, A. Ganem-Rondero, and D. Lechuga-Ballesteros Single emulsion-solvent evaporation technique and modifications for the preparation of pharmaceutical polymeric nanoparticles Recent Patents Drug Deliv. Formul. 6 2012 209 223
43. X.Z. Yang, S. Dou, T.M. Sun, C.Q. Mao, H.X. Wang, and J. Wang Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy J. Control. Release 156 2011 203 211
44. A.K. Bisht, B. Bhushan, V. Dhiman, and R.K. Dhawan A novel gradient RP-HPLC method development for bortezomib in parenteral dosage form J. Biomed. Pharm. Res. 2 2013 10 15
45. Y.P. Liu, C.J. Yang, M.S. Huang, C.T. Yeh, A.T. Wu, Y.C. Lee, T.C. Lai, C.H. Lee, Y.W. Hsiao, J. Lu, C.N. Shen, P.J. Lu, and M. Hsiao Cancer Res. 73 2013 406 416
46. P.M. Voorhees, and R.Z. Orlowski The proteasome and proteasome inhibitors in cancer therapy Annu. Rev. Pharmacol. Toxicol. 46 2006 189 213
47. T.M. Sun, Y.C. Wang, F. Wang, J.Z. Du, C.Q. Mao, C.Y. Sun, R.Z. Tang, Y. Liu, J. Zhu, Y.H. Zhu, X.Z. Yang, and J. Wang Cancer stem cell therapy using doxorubicin conjugated to gold nanoparticles via hydrazone bonds Biomaterials 35 2014 836 845
48. C. Ginestier, M.H. Hur, E. Charafe-Jauffret, F. Monville, J. Dutcher, M. Brown, J. Jacquemier, P. Viens, C.G. Kleer, S. Liu, A. Schott, D. Hayes, D. Birnbaum, M.S. Wicha, and G. Dontu ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome Cell Stem Cell 1 2007 555 567
49. J. Douville, R. Beaulieu, and D. Balicki ALDH1 as a functional marker of cancer stem and progenitor cells Stem Cells Dev. 18 2009 17 25
50. V.P. Torchilin Multifunctional nanocarriers Adv. Drug Deliv. Rev. 58 2006 1532 1555